Suppr超能文献

通过皮肤微透析评估西替利嗪和氯雷他定对体内人皮肤中可待因诱导的组胺释放的影响。

The effect of cetirizine and loratadine on codeine-induced histamine release in human skin in vivo assessed by cutaneous microdialysis.

作者信息

Perzanowska M, Malhotra D, Skinner S P, Rihoux J P, Bewley A P, Petersen L J, Church M K

机构信息

Immunopharmacology Group, Southampton General Hospital, UK.

出版信息

Inflamm Res. 1996 Sep;45(9):486-90. doi: 10.1007/BF02252321.

Abstract

OBJECTIVE AND DESIGN

To determine whether or not cetirizine and loratadine inhibit codeine- induced histamine release in human skin in vivo, we conducted a placebo-controlled double-blind trial in which histamine release was assessed by dermal microdialysis.

SUBJECTS

A group of ten normal volunteers were studied, each subject visiting the laboratory on three occasions with intervals of at least 2 weeks between visits.

TREATMENT

Cetirizine, loratadine (both 10 mg) or placebo was given orally 4 h before provocation of weal and flare responses in the skin by intradermal injection of 25 microliters of 3 or 10 mg/ml codeine 1 mm from the centre of individual 216 microns diameter microdialysis fibres inserted in the dermis.

METHODS

Dialysate was collected at 2 min intervals for 4 min before and 20 min after codeine injection and histamine assayed spectrofluorometrically. Weal and flare responses to codeine were assessed in the opposite arm.

RESULTS

Histamine concentrations in the microdialysis fibre outflow with 3 and 10 mg/ml codeine were maximal at 2-4 min when 910 +/- 156 and 1194 +/- 304 nM respectively were found in the placebo group. Cetirizine and loratadine did not modify either the kinetics or total histamine release while significantly (p < 0.01) inhibiting weal and flare responses.

CONCLUSIONS

Neither cetirizine nor loratadine inhibited codeine-induced histamine release or modified the time course of its release in human skin in vivo when given in clinically used doses which are sufficient to significantly reduce weal and flare responses.

摘要

目的与设计

为了确定西替利嗪和氯雷他定是否能在体内抑制人皮肤中可待因诱导的组胺释放,我们进行了一项安慰剂对照双盲试验,通过皮肤微透析评估组胺释放情况。

受试者

研究了一组十名正常志愿者,每位受试者分三次到实验室,每次就诊间隔至少2周。

治疗

在通过皮内注射25微升3或10毫克/毫升可待因(距插入真皮的直径216微米的单个微透析纤维中心1毫米处)诱发皮肤风团和潮红反应前4小时,口服西替利嗪、氯雷他定(均为10毫克)或安慰剂。

方法

在注射可待因前4分钟和注射后20分钟,每隔2分钟收集一次透析液,并用荧光分光光度法测定组胺含量。在对侧手臂评估对可待因的风团和潮红反应。

结果

安慰剂组中,3毫克/毫升和10毫克/毫升可待因使微透析纤维流出液中的组胺浓度在2 - 4分钟时达到最高,分别为910±156纳摩尔和1194±304纳摩尔。西替利嗪和氯雷他定既未改变组胺释放的动力学,也未改变组胺的总释放量,但能显著(p<0.01)抑制风团和潮红反应。

结论

当给予足以显著减轻风团和潮红反应的临床常用剂量时,西替利嗪和氯雷他定均不能在体内抑制人皮肤中可待因诱导的组胺释放,也不能改变其释放的时间进程。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验